Craig-Hallum Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $12
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsInitiationPrice Target
Craig-Hallum analyst Adam Vogel initiates coverage on Alterity Therapeutics (NASDAQ:ATHE) with a Buy rating and announces Price Target of $12.
Craig-Hallum analyst Adam Vogel initiates coverage on Alterity Therapeutics (NASDAQ:ATHE) with a Buy rating and announces Price Target of $12.